Physiomics Regulatory News (PYC)

The following amendment has been made to the 'Issue of Equity' announcement released on 30 January 2014 at 15.02 under RNS No 9183Y.

The ordinary shares were issued at a price of 0.175p, not 0.0175p as previously stated.

All other details remain unchanged.

The full amended text is shown below.

Physiomics plc

("Physiomics") or ("the Company") 

Issue of Equity

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has issued 11,428,571 ordinary shares, pursuant to fees arising under its Standby Equity Distribution Agreement ("SEDA"), to YA Global Master SPV Ltd ("YA") at a price of 0.175p.

Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 6 February 2014.

Following this issue of Ordinary Shares, the total number of shares in issue will increase to 1,719,157,921.

Enquiries:

Physiomics plc

Mark Chadwick 

+44 (0)1865 784980

WH Ireland Limited

Katy Mitchell

+44 (0) 161 832 2174

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002